{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(10)"],"submitter":["Yasuma T"],"pubmed_abstract":["Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy."],"journal":["International journal of molecular sciences"],"pagination":["E2902"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6213486"],"repository":["biostudies-literature"],"pubmed_title":["Renal Injury during Long-Term Crizotinib Therapy."],"pmcid":["PMC6213486"],"pubmed_authors":["Baffour Tonto P","Yonemura S","Kobayashi T","Nishihama K","Toda M","Takeshita A","Fujimoto H","Taguchi O","Yasuma T","Ito K","D'Alessandro-Gabazza CN","Gabazza EC","Nishii Y","Hataji O"],"additional_accession":[]},"is_claimable":false,"name":"Renal Injury during Long-Term Crizotinib Therapy.","description":"Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2026-07-15T18:15:59.503Z","creation":"2025-05-31T22:24:59.698Z"},"accession":"S-EPMC6213486","cross_references":{"pubmed":["30257437"],"doi":["10.3390/ijms19102902"]}}